Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Lidocaine for Pediatric Migraine in the ED
NCT03576820Phase 3Unknown
- Sponsor
- NYC Health + Hospitals
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine 10% oropharyngeal spray in migraine (2 arms), sponsored by NYC Health + Hospitals. Primary endpoint: Change in Pain Score (NRS) at 20 months. Status: unknown.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03576820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576820.